Pacira | PCRX - Selling And Administration Expenses


Pacira reported $91.8M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Astellas Pharma JPY 206.84B 9.84B Sep/2025
Bristol-Myers Squibb USD 1.79B 76M Sep/2025
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
J&J USD 6.75B 831M Dec/2025
Ligand Pharmaceuticals USD 28.45M 8.27M Sep/2025
Novo Nordisk DKK 18.85B 2.74B Jun/2025
Pacira USD 91.8M 14.6M Sep/2025
Perrigo USD 245.7M 27.4M Sep/2025
Pfizer USD 3.19B 209M Sep/2025
Supernus Pharmaceuticals USD 179.68M 117.46M Sep/2025
Teva Pharmaceutical Industries USD 1.12B 147M Dec/2025
Xeris Pharmaceuticals USD 46.46M 2.07M Sep/2025
Zoetis USD 579M 29M Sep/2025